In silico drug design helps to greatly reduce both the time and cost of your project without any compromise of the accuracy.
One of the main challenges facing modern drug design is to find new biologically active lead compounds, i.e. those which can bind to a target protein, and to reduce the price for such a project. For instance, if one tries to screen a library of 200 000 compounds, one will have to spend about 20 million US dollars only for these chemicals and much more for the other necessary reagents. Even screening of an inefficiently small collection of 2000 compounds will cost about 200K dollars for the chemicals.
In silico drug design helps to greatly reduce both the time and cost of your project. It comprises a vast number of advanced scientific computational techniques and resources. Therefore, in silico drug design is not only a powerful tool for discovering novel potential drugs, but it can also lead to a huge cut in the required funding for this goal. Correspondingly, it is widely employed nowadays in big pharmaceutical companies. Many corporations suggest in silico methodologies either for screening new lead compounds or for an examination of the potential toxicity of already known chemicals.
However, most of their services are limited to one or few approaches, such as, for example, QSAR methods, which results in inefficient detection of the compounds activity, small possible structural diversity, and many other scientific problems.
We, at Micar21 Ltd., provide a modern scheme for the screening of millions of compounds and the discovery of new leads, based on the combination of the most advanced approaches nowadays, which ensures the success of your project!
... see scientific information